FIGURE 4 Glucagon-like peptide-1 receptor agonist-related other neoplasms Supplementary Figure S6 and Figure 5 demonstrate that the lower limit of PRR for GLP-1RA-associated bile duct cancer was greater than 1 in the first three models but less than 1 in model 4 (PRR 1.42, 95% CI 0.962.10, p = 0.03) and model 5 (PRR 1.39, 95% CI 0.952.03, p = 0.09)
As companion supplements, the evidence-backed ones (protein, fiber, electrolytes, key vitamins) genuinely help you tolerate the drug and keep muscle
Hormonal Research Beyond appetite and glucose regulation, GLP1-S has attracted attention for its potential effects on wider endocrine systems
Keep a symptom diary noting when itching occurs, its intensity, and what you were doing (eating, exercising, sleeping) to identify patterns
Based on these data, the IGF-1 drug itself does not cause oncology, but only has a contraindication to use if you already have cancer or its predisposition (high cancer markers)
Many patients begin to see weight loss within the first few weeks of treatment, with more significant results becoming evident over several months